Acesion Pharma

Acesion Pharma is a clinical-stage biotech company developing first-in-class therapies for atrial fibrillation by targeting the SK ion channel, a novel antiarrhythmic mechanism. The company has advanced its lead candidate, AP30663, through Phase 2 and has initiated a Phase 2 trial for a next-generation candidate, AP31969. Backed by a world-class scientific advisory board and private investment, Acesion aims to address the significant unmet need for safer, more effective cardioversion and rhythm control treatments in a large and growing market.

Pioneering small-molecule inhibitors of the Small-Conductance Calcium-Activated Potassium (SK) ion channel for atrial-selective treatment of atrial fibrillation.

Acesion competes with established antiarrhythmic drugs (e.g., amiodarone, flecainide, dronedarone), generic alternatives, and advancing catheter ablation technologies. Its differentiation is based on a first-in-class, atrial-selective mechanism aiming for superior safety, particularly regarding ventricular pro-arrhythmia.